Personalized Analgesia Through Central Nervous System Engagement to Unlock Performance
- NCT ID
- NCT07759336
- Registry status
- Not yet recruiting
- Study type
- Interventional
- Phase
- Phase 4
- Sponsor
- Benedict Alter
- Conditions
- Chronic Knee Pain, Chronic Pain, Knee Osteoarthritis (Knee OA)
Overview
ClinicalTrials.gov lists this study as Not yet recruiting.
Enrollment: 85 participants (Estimated).
What is being studied
- Drug: Duloxetine
- Intervention: Duloxetine Hydrochloride
- Intervention: Heterocyclic Compounds
- Intervention: Heterocyclic Compounds, 1-Ring
- Intervention: Organic Chemicals
- Drug: Placebo
- Intervention: Sulfur Compounds
- Intervention: Thiophenes
Who may be eligible
- Ages
- 45 Years to 80 Years
- Sex
- All
- Healthy volunteers accepted
- No
ClinicalTrials.gov lists the following eligibility criteria.
Inclusion Criteria:
* Knee pain for greater than 6 months.
* Moderate-to-severe knee pain (\>3/10) due to osteoarthritis, as defined by American College of Rheumatology and EULAR diagnostic criteria (Zhang 2010, Altman 1986) on \>50% of days in the past month.
* KL grade 2-4 (Kellgren and Lawrence 1957) indicating significant degenerative changes on knee X-ray. This will be determined on evaluation of weight-bearing clinical X-rays on review of medical records. In the infrequent situation that the patient does not have an X-ray on review of their medical records, then the patient will obtain weight-bearing knee X-rays as part of the Screening Visit.
* Age: 45-80 years old
* Gender: Males and females will be recruited.
* Language: only English-speaking subjects will be included.
Exclusion Criteria:
* Inflammatory arthritis (e.g. rheumatoid arthritis).
* More intense pain due to another chronic pain syndrome (e.g. fibromyalgia, hip osteoarthritis)
* Significant pain or weakness in the lower extremities due to a neurological condition (e.g. lumbar radiculopathy, paresis due to stroke)
* New, ongoing acute pain
* Recent use of duloxetine defined as any use within the last 3 months
* Current use of antidepressants or tramadol
* Current routine use of more than 30 mg oral morphine equivalents per day (use of \<=30 mg OME does not exclude the participant).
* New treatment that may help knee osteoarthritis (including medication, exercise, behavioral, or complementary and integrative treatments) started in the last month. Stable use of treatments for greater than 1 month does not exclude the participant.
* Unwillingness to maintain current knee osteoarthritis treatments for the duration of the study. This means that eligible participants must plan for the following: medications and dietary supplements should not change substantially in frequency or dose; behavioral therapy, exercise therapy, and complementary and integrative therapies should be consistent; and there should be no interventional treatments planned for lower extremity musculoskeletal conditions (e.g. joint steroid injections, knee radiofrequency ablation, knee replacement surgery).
* Recent knee intra-articular injection of steroid or other agent (greater than 1 month does not exclude the participant)
* Recent knee radiofrequency ablation (greater than 3 months does not exclude the participant)
* Recent knee arthroscopic surgery (greater than 3 months does not exclude the participant)
* History of knee replacement or open knee surgery on the index knee, defined as the more painful knee on average over the last month.
* Inability to walk or climb stairs without significant assistance (e.g. a one-person assist, use a wheelchair; use of a cane does not exclude the participant).
* Inability to participate in study procedures (e.g. cognitive impairment limiting ability to understand directions, inability to understand and read English)
* Uncontrolled or unstable medical disorder preventing participation in study procedures
* History of brain surgery
* Tattoos on sensory testing sites
* Pregnancy
* History of severe renal impairment defined by GFR \< 30 ml/min or, if renal function testing is not available on EMR review, patient-reported history of acute or chronic kidney disease of any severity
* History of chronic liver disease or cirrhosis
* History of angle-closure glaucoma
Study locations
1 study location is listed.
Site recruitment status is not specified in the registry data for these locations.
Countries: United States
- Pennsylvania, United States: 1
Sample of listed locations
- University of Pittsburgh - Center for Innovation in Pain Care (Research) — Pittsburgh, Pennsylvania, 15206, United States — Site recruitment status not specified in the registry data
Study details
- Start date
- August 1, 2026
- Primary completion date
- August 1, 2028
- Completion date
- August 1, 2028
- First posted
- August 12, 2026
- Collaborators
- National Institute of Neurological Disorders and Stroke (NINDS)
Source and update information
- Source
- ClinicalTrials.gov
- NCT ID
- NCT07759336
- Registry last updated
- August 12, 2026
- QualifiedStudies registry data refreshed
- October 2, 2026
- QualifiedStudies record fetched
- October 2, 2026
View NCT07759336 on ClinicalTrials.gov
Trial information can change. Confirm current study details with the study team or the registry.
About joining clinical research
Find clinical trials you may match with
QualifiedStudies can help you search for research opportunities related to your health. Availability of this specific study through QualifiedStudies has not been established.
Find clinical trials you may match with | Clinical trial FAQ